Literature DB >> 24910165

Diffusion restriction in a non-enhancing metastatic brain tumor treated with bevacizumab - recurrent tumor or atypical necrosis?

Lakshmanan Sivasundaram1, Saman Hazany2, Naveed Wagle3, Gabriel Zada4, Thomas C Chen4, Alexander Lerner2, John L Go2, Francesco D'Amore2, Meng Law2, Mark S Shiroishi2.   

Abstract

A 38-year-old female with metastatic brain cancer developed non-enhancing, diffusion restricted lesions following bevacizumab treatment. From our review of the literature, this is the first reported case of this type of lesion. Clinicians should be wary of these lesions, as they can represent either tumor progression or necrosis/effects of chronic hypoxia from anti-angiogenic therapy. Further investigation is necessary to determine the biological mechanism and clinical significance of this type of imaging appearance.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Atypical necrosis; Bevacizumab; Brain metastases; DWI; Recurrent tumor

Mesh:

Substances:

Year:  2014        PMID: 24910165     DOI: 10.1016/j.clinimag.2014.04.014

Source DB:  PubMed          Journal:  Clin Imaging        ISSN: 0899-7071            Impact factor:   1.605


  3 in total

Review 1.  Physiologic MRI for assessment of response to therapy and prognosis in glioblastoma.

Authors:  Mark S Shiroishi; Jerrold L Boxerman; Whitney B Pope
Journal:  Neuro Oncol       Date:  2015-09-12       Impact factor: 12.300

2.  Diagnostic Accuracy of Centrally Restricted Diffusion in the Differentiation of Treatment-Related Necrosis from Tumor Recurrence in High-Grade Gliomas.

Authors:  N Zakhari; M S Taccone; C Torres; S Chakraborty; J Sinclair; J Woulfe; G H Jansen; T B Nguyen
Journal:  AJNR Am J Neuroradiol       Date:  2017-12-07       Impact factor: 3.825

3.  Cerebral Metastases of Lung Cancer Mimicking Multiple Ischaemic Lesions - A Case Report and Review of Literature.

Authors:  Anna Zacharzewska-Gondek; Hanna Maksymowicz; Małgorzata Szymczyk; Marek Sąsiadek; Joanna Bladowska
Journal:  Pol J Radiol       Date:  2017-09-15
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.